Search results
Results From The WOW.Com Content Network
Valsartan, sold under the brand name Diovan among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. [8] It belongs to a class of medications referred to as angiotensin II receptor blockers (ARBs). It is a reasonable initial treatment for high blood pressure. [8] It is taken by mouth.
Later in 2021 and 2022, several cases of contamination with azido impurities were detected in losartan, irbesartan, and valsartan, prompting regulatory responses ranging from investigation to market withdrawals and precautionary recalls in Australia, [79] Brazil, [80] and Europe (including Switzerland). [81] [82]
Mylan N.V. Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer 's off-patent medicine division, to form Viatris. [1] Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK [2] and a "Global Center" in ...
Losartan, valsartan, candesartan, irbesartan, telmisartan and olmesartan all contain a biphenyl-methyl group. Losartan is partly metabolized to its 5- carboxylic acid metabolite EXP 3174, which is a more potent AT 1 receptor antagonist than its parent compound [ 17 ] and has been a model for the continuing development of several other ARBs.
In 2018, [22] and 2019, [23] Aurobindo Pharma USA recalled tablets containing valsartan due to the detection of N-Nitrosodiethylamine (NDEA) which is a probable human carcinogen. In November 2019, Aurobindo Pharma USA recalled ranitidine tablets, capsules, and syrup due to the detection of unacceptable levels of N-nitrosodimethylamine (NDMA). [24]
Recalls [ edit ] In 2018-2019, Teva Pharmaceuticals USA recalled antihypertensive tablets containing valsartan and losartan due to the detection beyond acceptable limit of N -nitrosodiethylamine (NDEA) and N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), respectively, which are probable human carcinogens.
Sacubitril/valsartan, sold under the brand name Entresto among others, is a fixed-dose combination medication for use in heart failure. It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan. The combination is sometimes described as an "angiotensin receptor-neprilysin inhibitor" (ARNi). [ 9 ]
Amlodipine/valsartan, sold under the brand name Exforge among others, is a blood pressure lowering combination drug. It contains amlodipine, as the besilate, a dihydropyridine -type calcium channel blocker, and valsartan, an angiotensin II receptor antagonist. [6] This combination is usually well tolerated and effective for the reduction of ...